ISO 18310-2 is second in the series of documents on measurement and predictions of ambient dose equivalent. ISO 18310-2 addresses the measurement methods, procedures, and uncertainty estimation for the measurement, using a personal dosimeter, of the effective dose to the caregiver in the vicinity of the patient treated with radioiodine to ablate the thyroid.
ISO 18310-2 provides the general requirements for the patient and caregiver and guidance for a designated expert on instructing caregivers of discharged patients is considered to effectively measure the effective dose to the caregiver in the vicinity of the patient.
ISO 18310-2 on measurement and predictions of ambient dose equivalent is useful for:
Radioiodine is a common and effective treatment for thyroid cancer. There are, however, significant radiation protection issues associated with treatment. These include emitted radiation and the loss of radioiodine through urine, faeces, sweat, saliva and breast milk. Those at potential risk of being irradiated include members of the public and caregivers with whom the patient may come into close proximity.
ISO 18310-2 provides the general requirements for the patient and caregiver and guidance for a designated expert on instructing caregivers of discharged patients is considered to effectively measure the effective dose to the caregiver in the vicinity of the patient.
ISO 18310-2 helps in the determination of the effective dose to the caregiver in the vicinity of the patient treated with radioiodine. It is based on the estimation of the effective dose using a personal dosimeter worn by the caregiver. The uncertainty of the effective dose is also provided.
The guidance provided in ISO 18310-2 can help you to improve the safety of caregivers of patients who underwent radioiodine treatment by enabling you to measure the suitable dosage to prevent radiation poisoning.
ISO 18310-2